<DOC>
	<DOCNO>NCT01203371</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety Naftopidil Tamsulosin treatment low urinary tract symptom comparative study patient benign prostatic hyperplasia .</brief_summary>
	<brief_title>Efficacy And Safety Study Of Naftopidil Patients Treatment With LUTS</brief_title>
	<detailed_description>Inclusion Criteria : Men ≥ 50 year Signs symptoms BPH A total IPSS ≥ 10 Prostate volume ≥20 mL ( estimate ultrasonography ) PVR &gt; 150mL</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Naftopidil</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Men ≥ 50 year Signs symptoms BPH IPSS ≥ 10 Prostate volume ≥ 20 mL PVR &gt; 150 mL History allergy AR antagonists Treatment antiandrogen drug Drugs anticholinergic activity Significant history orthostatic hypotension Concomitant neurological disease Known suspect neurogenic bladder dysfunction Carcinoma prostate bladder Previous surgery BPH bladder neck obstruction History recurrent UTI Concomitant active UTI</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>naftopidil</keyword>
	<keyword>symptom low urinary tract</keyword>
	<keyword>benign prostate hyperplasia</keyword>
	<keyword>LUTS</keyword>
</DOC>